The Scientist - USA (2020-11)

SARS-CoV-2 is characterized by its rapid spread and significant human-to-human transmission. With no approved vaccines or treatments yet available,

researchers are exploring various medical interventions, including neutralizing monoclonal antibodies (mAbs), to control the global COVID-19 pandemic.

The SARS-CoV-2 spike (S) glycoprotein, which promotes entry into host cells, is the main target of neutralizing antibodies. In this multisponsored webinar

by The Scientist, a panel of researchers will discuss potential neutralizing antibodies currently under investigation for COVID-19 treatment.

JAMES E. CROWE, JR., MD

Director, Vanderbilt Vaccine Center

Professor, Pediatrics and Pathology, Microbiology

and Immunology

Ann Scott Carrell Chair

DEVIN SOK, PHD

Senior Director, Antibody Discovery and Development

IAVI

WATC H NOW!

http://www.the-scientist.com/putting-the-brakes-on-sars-cov-2

TOPICS COVERED

• Human monoclonal antibodies for SARS-CoV-2


• SARS-CoV-2 neutralizing antibodies for global access

ORIGINALLY AIRED

TUESDAY, JULY 28, 2020

ONDEMAND Putting the Brakes on SARS-CoV-2: Neutralizing Antibodies

WEBINAR SPONSORED BY

Hematopoietic stem and progenitor cells (HSPCs) are capable of generating a large diversity of blood cells throughout the human lifespan. Although these

cells have been extensively evaluated, there remains significant uncertainty in the degree of heterogeneity within HSPC subpopulations and their associated

differentiation trajectories. Identifying HSPC phenotypic diversity is important for better understanding the pathogenesis of numerous blood disorders, including

hematologic malignancies. In this webinar sponsored by BD Biosciences, Margaret Nakamoto will introduce the BD Rhapsody™ Single-Cell Analysis System, and

Ravi Majeti will discuss how he and his team used concurrent RNA and BD® AbSeq Antibody-oligo multiplexed surface marker analysis

to improve HSPC clustering and characterize specific phenotypic states along unique hematopoietic differentiation trajectories.

MARGARET NAKAMOTO, PHD

Manager, Genomics

BD Biosciences

RAVI MAJETI, MD, PHD

Professor of Medicine

Chief, Division of Hematology

Institute for Stem Cell Biology and Regenerative Medicine

Stanford University School of Medicine

WATC H NOW!

https://www.the-scientist.com/HSPCSingleCellAbseq

TOPICS COVERED

• Application of single-cell multiomics to healthy bone
  marrow mononuclear cells (BMMCs)


• Identification of cell type clusters and surface marker
  associations using combined single-cell whole transcriptome
  amplification and surface marker analysis


• Correlation of cell types with both canonical and novel
  surface markers and how deconvolution analysis provides
  preliminary insights into their potential clinical relevance in
  acute myeloid leukemia (AML)

ORIGINALLY AIRED

THURSDAY, AUGUST 13, 2020

ONDEMAND

Multiomic Single-Cell Analysis Identifies a Unique Stem

and Progenitor Population

WEBINAR SPONSORED BY